Greehey CCRI Archives
Pediatric Blood & Cancer: Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models
October 28, 2017Abhik Bandyopadhyay 1, Edward Favours 1, Doris A Phelps 1, Vanessa Del Pozo 1, Samson Ghilu 1, Dias Kurmashev 1, Joel Michalek 2, Aron Trevino 2, Denis Guttridge 3, Cheryl London 4, Kenji Hirotani 5, Ling Zhang 5, Raushan T Kurmasheva 1, Peter J Hought …
Cancer Research: Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis
October 1, 2016Brendan Murphy 1, Han Yin 1, John M Maris 2, E Anders Kolb 3, Richard Gorlick 4, C Patrick Reynolds 5, Min H Kang 6, Stephen T Keir 7, Raushan T Kurmasheva 8, Igor Dvorchik 9, Jianrong Wu 10, Catherine A Billups 10, Nana Boateng 10, Malcolm A Smith 11, …
Pediatric Blood & Cancer: Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program
September 21, 2016Richard Lock 1, Hernan Carol 1, John M Maris 2, E Anders Kolb 3, Richard Gorlick 4, C Patrick Reynolds 5, Min H Kang 5, Stephen T Keir 6, Jianrong Wu 7, Andrei Purmal 8, Andrei Gudkov 9, Dias Kurmashev 10, Raushan T Kurmasheva 10, Peter J Houghton 10, …
Cancer Chemotherapy and Pharmacology: Identifying novel therapeutic agents using xenograft models of pediatric cancer
May 18, 2016Raushan T. Kurmasheva & Peter J. Houghton Abstract In the USA, the overall cure rate for all childhood cancers is seventy percent, and in many patients that ultimately fail curative therapy, initial responses to current multimodality treatments (su …
Pediatric Blood & Cancer: Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program
March 1, 2016Richard Gorlick 1, E Anders Kolb 2, Stephen T Keir 3, John M Maris 4, Richard B Lock 5, Hernan Carol 5, C Patrick Reynolds 6, Min H Kang 6, Catherine A Billups 7, Jerry Collins 8, Dias Kurmashev 9, Raushan T Kurmasheva 9, Peter J Houghton 9, Malcolm A …
Pediatric Blood & Cancer: Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program
February 1, 2016Edward F Attiyeh, John M Maris 1, Richard Lock 2, C Patrick Reynolds 3, Min H Kang 3, Hernan Carol 2, Richard Gorlick 4, E Anders Kolb 5, Stephen T Keir 6, Jianrong Wu 7, Yosef Landesman 8, Sharon Shacham 8, Dmitry Lyalin 9, Raushan T Kurmasheva 9, Pet …
Business Wire: Epizyme to Present New Scientific Data on the Role of HMT Inhibitors in Cancer
November 4, 2015CAMBRIDGE, Mass.–(BUSINESS WIRE)–Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, will present data from 11 accepted abstracts on the role of histone methyltransferase ( …
Pediatric Blood & Cancer: Inhibition of MEK confers hypersensitivity to X-radiation in the context of BRAF mutation in a model of childhood astrocytoma
October 1, 2015Adam Studebaker 1, Kathryn Bondra 2, Star Seum 2, Changxian Shen 1, Doris A Phelps 1, Christopher Chronowski 2, Justin Leasure 2, Paul D Smith 3, Raushan T Kurmasheva 1, Xiaokui Mo 4, Maryam Fouladi 5, Peter J Houghton 1 Abstract Purpose: Curative ther …
NCI PPTC: Sarcoma and Renal Tumor Research Program
September 1, 2015Dr. Peter Houghton, Dr. Raushan Kurmasheva (Co-Investigator) Dr. Houghton is the Director of the Greehey Children’s Cancer Research Institute, which has as its mission to advance scientific knowledge relevant to childhood cancer and to accelerat …
Frontiers in Oncology: Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation
August 26, 2015Over the past 35 years, cure rates for pediatric cancers have increased dramatically. However, it is clear that further dose intensification using cytotoxic agents or radiation therapy is not possible without enhancing morbidity and long-term effects. …
- Previous Page 5 out of 5